NGM Bio Begins Phase 2 Trial for Potential Hyperemesis Gravidarum Treatment

NGM Biopharmaceuticals, Inc. (NGM Bio) has officially dosed the first participant in its EMERALD Phase 2 clinical study of NGM120, a novel GFRAL antagonist designed to block GDF15 activity, for the treatment of hyperemesis gravidarum (HG). As a severe and debilitating pregnancy condition, HG causes persistent nausea and vomiting, leading to dehydration, weight loss, and malnutrition. With no approved therapies targeting the root cause, NGM120 represents a promising advancement in addressing this urgent medical need.

The trial builds on the understanding that heightened GDF15 levels contribute to HG symptoms. By blocking GDF15’s interaction with its receptor, NGM120 may help alleviate the severe nausea and vomiting experienced by affected patients. “HG is often underappreciated in its severity, and we hear the desperate need for effective treatments,” said Wendy Yeh, M.D., Chief Medical Officer at NGM Bio. With this Phase 2 trial, NGM Bio aims to provide hope to countless women struggling with this life-altering condition.